{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:16:35Z","timestamp":1794575795590,"version":"4.9.1"},"reference-count":8,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:p>\n                    PSMA-targeted radioligand therapy (RLT) is effective in metastatic castration-resistant prostate cancer, but interpretation is challenging when PSA rises despite apparent response on post-therapy\n                    <jats:sup>177<\/jats:sup>\n                    Lu-PSMA SPECT\/CT. We present 2 patients with this PSA-PSMA discordance after 2 cycles:\n                    <jats:sup>177<\/jats:sup>\n                    Lu-PSMA post-therapy SPECT\/CT showed a significant reduction in PSMA-derived tumor volume, yet PSA levels progressed.\n                    <jats:sup>18<\/jats:sup>\n                    F-FDG PET\/CT performed after 2 cycles clarified disease status by revealing new hypermetabolic skeletal and visceral lesions, consistent with progression. PSMA-targeted RLT was discontinued early in both cases.\n                    <jats:sup>18<\/jats:sup>\n                    F-FDG PET\/CT may resolve discordant PSA and PSMA findings and help prevent futile continuation of ineffective PSMA\u2011targeted RLT.\n                  <\/jats:p>","DOI":"10.1097\/rlu.0000000000006260","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:00:14Z","timestamp":1767650414000},"page":"191-193","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Added Value of Interim FDG PET\/CT in Resolving PSA-PSMA Discordance during PSMA-targeted Radioligand Therapy"],"prefix":"10.1097","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7056-1749","authenticated-orcid":false,"given":"Mutaz","family":"Kassas","sequence":"first","affiliation":[{"name":"Department of Nuclear Medicine, Institut Jules Bordet, H\u00f4pital Universitaire de Bruxelles, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Artigas","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Institut Jules Bordet, H\u00f4pital Universitaire de Bruxelles, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Refalo","sequence":"additional","affiliation":[{"name":"Department of Oncology, Sir Anthony Mamo Oncology Centre, Msida, Malta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Mallia","sequence":"additional","affiliation":[{"name":"Department of Medical Imaging, Division of Nuclear Medicine, Mater Dei Hospital, Msida, Malta"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Flamen","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Institut Jules Bordet, H\u00f4pital Universitaire de Bruxelles, Universit\u00e9 Libre de Bruxelles, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,8]]},"reference":[{"key":"R1-20260107","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.2967\/jnumed.119.240242","article-title":"Early prostate-specific antigen changes and clinical outcome after (177)Lu-PSMA radionuclide treatment in patients with metastatic castration-resistant prostate cancer","volume":"61","author":"Gafita","year":"2020","journal-title":"J Nucl Med"},{"key":"R2-20260107","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00259-017-3877-z","article-title":"Delayed response after repeated (177)Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer","volume":"45","author":"Rahbar","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R3-20260107","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1007\/s00259-022-05910-w","article-title":"mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease","volume":"49","author":"Hartrampf","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R4-20260107","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","article-title":"Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study","volume":"36","author":"Aggarwal","year":"2018","journal-title":"J Clin Oncol"},{"key":"R5-20260107","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1007\/s00259-020-05160-8","article-title":"Prognostic implications of dual tracer PET\/CT: PSMA ligand and [(18)F]FDG PET\/CT in patients undergoing [(177)Lu]PSMA radioligand therapy","volume":"48","author":"Michalski","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R6-20260107","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.3390\/cancers13164134","article-title":"Value of combined PET imaging with [(18)F]FDG and [(68)Ga]Ga-PSMA-11 in mCRPC patients with worsening disease during [(177)Lu]Lu-PSMA-617 RLT","volume":"13","author":"Khreish","year":"2021","journal-title":"Cancers (Basel)"},{"key":"R7-20260107","doi-asserted-by":"crossref","first-page":"1607227","DOI":"10.3389\/fmed.2025.1607227","article-title":"Diagnostic value of dual-tracer PET\/CT with [(18)F]FDG and PSMA ligands in prostate cancer: an updated systematic review","volume":"12","author":"Iacovitti","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"R8-20260107","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006260","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:52:37Z","timestamp":1786042357000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/RLU.0000000000006260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,8]]},"references-count":8,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000006260","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,8]]},"assertion":[{"value":"2025-10-02","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-04","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}